Dynamic Contrast-enhanced Imaging Research Articles

Multiparametric MRI Radiomics With Machine Learning for Differentiating HER2-Zero, -Low, and -Positive Breast Cancer: Model Development, Testing, and Interpretability Analysis.

BACKGROUND: MRI radiomics has been explored for three-tiered classification of breast cancer HER2 expression (i.e., HER2-zero, HER2-low, or HER2-positive), although understanding of how such models reach their predictions is lacking. OBJECTIVE: To develop and test multiparametric MRI radiomics machine-learning models for differentiating three-tiered HER2 expression levels in patients with breast cancer, and to explain the contributions of model features through local and global interpretations using SHapley Additive exPlanation (SHAP) analysis. METHODS: This retrospective study included 737 patients (mean age, 54.1±10.6 years) with breast cancer from two centers (center 1: n=578; center 2: n=159), who underwent breast MRI and had HER2 expression determined after excisional biopsy. Analysis entailed two tasks: differentiating HER2-negative (i.e., HER2-zero or HER2-low) from HER2-positive tumors (task 1), and differentiating HER2-zero from HER2-low tumors (task 2). For each task, patients from center 1 were randomly assigned in 7:3 ratio to training (task 1: n=405; task 2: n=284) or internal test (task 1: n=173; task 2: n=122) sets; those from center 2 formed an external test set (task 1: n=159; task 2: n=105). Radiomics features were extracted from early-phase dynamic contrast-enhanced images (DCE), T2-weighted images (T2WI), and DWI. For each task, a support vector machine (SVM) was used for feature selection; a multiparametric radiomics score (radscore) was computed using feature weights from SVM correlation coefficients; conventional MRI and combined models were constructed; and model performances were evaluated. SHAP analysis was used to provide local and global interpretations for model outputs. RESULTS: In the external test set, for task 1, AUCs for the conventional MRI model, radscore, and combined model were 0.624, 0.757, and 0.762, respectively; for task 2, AUC for radscore was 0.754, and no conventional MRI model or combined model could be constructed. SHAP analysis identified early-phase DCE features as having the strongest influence for both tasks; T2WI features also had a prominent role for task 2. CONCLUSION: The findings indicate suboptimal performance of MRI radiomics models for noninvasive characterization of HER2 expression. CLINICAL IMPACT: The study provides an example of the use of SHAP interpretation analysis to better understand predictions of imaging-based machine learning models.

The Diagnostic Value of bpMRI in Prostate Cancer: Benefits and Limitations Compared to mpMRI.

Prostate cancer is the second most common cancer in men and a leading cause of death worldwide. Early detection is vital, as it often presents with vague symptoms such as nocturia and poor urinary stream. Diagnostic tools like PSA tests, ultrasound, PET-CT, and mpMRI are essential for prostate cancer management. The PI-RADS system helps assess malignancy risk based on imaging. While mpMRI, which includes T1, T2, DWI, and dynamic contrast-enhanced imaging (DCE), is the standard, bpMRI offers a contrast-free alternative using only T2 and DWI. This reduces costs, acquisition time, and the risk of contrast-related side effects but has limitations in detecting higher-risk PI-RADS 3 and 4 lesions. This study compared bpMRI's diagnostic accuracy to mpMRI, focusing on prostate volume and PI-RADS scoring. Both methods showed strong inter-rater agreement for prostate volume (ICC 0.9963), confirming bpMRI's reliability in this aspect. However, mpMRI detected more complex conditions, such as periprostatic fat infiltration and iliac lymphadenopathy, which bpMRI missed. While bpMRI offers advantages like reduced cost and no contrast use, it is less effective for higher-risk lesions, making mpMRI more comprehensive.

Micro-enema immediately prior to prostate MRI: effects on rectal gas, image quality and PI-QUAL score.

Our aim was to determine whether the administration of a micro-enema immediately prior to prostate MRI is associated with a reduction in rectal gas, gas related artifacts and an improvement in image quality and PI-QUAL score. This retrospective analysis enrolled 171 patients who underwent multiparametric 3T prostate MRI at our institution between January 2021 and September 2022. 86 patients received a micro-enema, and a further 85 patients did not. Two fellowship trained abdominal radiologists were blinded and independently reviewed each prostate MRI, recording scores on a dedicated scoring sheet. The quality of T2 weighted (T2W), diffusion weighted (DWI), and dynamic contrast enhancement (DCE) images were assessed according to standardised scales supported in the literature. In addition, gas related artifacts and rectal gas level were examined. An independent-samples Mann-Whitney U and t-test were performed, comparing both the median and mean score between micro-enema and no micro-enema groups for each reader. Spearman's correlation was used to determine the strength of relationship between variables. A quadratic weighted Cohen's Kappa and percent agreement were used to assess inter-observer agreement. Image quality was improved in those who received the micro-enema compared to those who did not according to the visual grading scale on the DWI sequence for both readers (reader 1: median 4 vs. 4, p < 0.001, mean 4.27 vs. 3.92, p < 0.001; reader 2: median 5 vs. 4, p < 0.001, mean 4.74 vs. 4.14, p < 0.001). PI-QUAL score was significantly improved in the micro-enema group for reader 2 only (reader 1: median 4 vs. 4, p = 0.25, mean 3.99 vs. 4.08, p = 0.21; reader 2: median 5 vs. 5, p = 0.01, mean 4.95 vs. 4.78, p = 0.01). Visual grading score for both the T2W and DCE images was not significantly different. Rectal gas level was lower in patients who received the micro-enema for both readers (reader 1: median 2 vs. 4, p < 0.001, mean 2.12 vs. 3.60, p < 0.001; reader 2: median 1 vs. 2, p < 0.001, mean 1.37 vs. 2.48, p < 0.001), correlating with a lower score for gas-related artifacts (reader 1: median 1 vs. 2, p < 0.001, mean 1.50 vs. 1.92, p < 0.001; reader 2: median 1 vs. 1, p < 0.001, mean 1.16 vs. 1.71, p < 0.001) in this group. Correlation between rectal gas level and gas-related artifacts on DWI regardless of whether a micro-enema was given was strong (rs = 0.71, p < 0.001). Correlation was moderate to strong between rectal gas level and image quality on DWI (rs = -0.63, p < 0.001). There was only 1 (1.2%) borderline diagnostic or non-diagnostic DWI sequence in those who received the micro-enema, compared to 9 (10.6%) in those who did not (p = 0.009). Interobserver agreement was moderate for image quality on DWI, gas related artifacts and rectal gas level (weighted kappa values of 0.52, 0.49 and 0.53 respectively). The administration of a micro-enema immediately prior to prostate MRI is associated with a significant improvement in image quality on the DWI sequence compared to no bowel preparation. This is mediated through a reduction in rectal gas and gas related artifacts. Improvements in PI-QUAL score was mixed between readers.

Quantitative Prostate MRI, From the AJR Special Series on Quantitative Imaging.

Prostate MRI has traditionally relied on qualitative interpretation. However, quantitative components hold the potential to markedly improve performance. The ADC from DWI is probably the most widely recognized quantitative MRI biomarker and has shown strong discriminatory value for clinically significant prostate cancer (csPCa) as well as for recurrent cancer after treatment. Advanced diffusion techniques, including intravoxel incoherent motion, diffusion kurtosis, diffusion tensor imaging, and specific implementations such as restriction spectrum imaging, purport even better discrimination, but are more technically challenging. The inherent T1 and T2 of tissue also provide diagnostic value, with more advanced techniques deriving luminal water imaging and hybrid-multidimensional MRI. Dynamic contrast-enhanced imaging, primarily using a modified Tofts model, also shows independent discriminatory value. Finally, quantitative size and shape features can be combined with the aforementioned techniques and be further refined using radiomics, texture analysis, and artificial intelligence. Which technique will ultimately find widespread clinical use will depend on validation across a myriad of platforms use-cases.

The application value of support vector machine model based on multimodal MRI in predicting IDH-1mutation and Ki-67 expression in glioma

PurposeTo investigate the application value of support vector machine (SVM) model based on diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) and amide proton transfer- weighted (APTW) imaging in predicting isocitrate dehydrogenase 1(IDH-1) mutation and Ki-67 expression in glioma.MethodsThe DWI, DCE and APTW images of 309 patients with glioma confirmed by pathology were retrospectively analyzed and divided into the IDH-1 group (IDH-1(+) group and IDH-1(-) group) and Ki-67 group (low expression group (Ki-67 ≤ 10%) and high expression group (Ki-67 > 10%)). All cases were divided into the training set, and validation set according to the ratio of 7:3. The training set was used to select features and establish machine learning models. The SVM model was established with the data after feature selection. Four single sequence models and one combined model were established in IDH-1 group and Ki-67 group. The receiver operator characteristic (ROC) curve was used to evaluate the diagnostic performance of the model. Validation set data was used for further validation.ResultsBoth in the IDH-1 group and Ki-67 group, the combined model had better predictive efficiency than single sequence model, although the single sequence model had a better predictive efficiency. In the Ki-67 group, the combined model was built from six selected radiomics features, and the AUC were 0.965 and 0.931 in the training and validation sets, respectively. In the IDH-1 group, the combined model was built from four selected radiomics features, and the AUC were 0.997 and 0.967 in the training and validation sets, respectively.ConclusionThe radiomics model established by DWI, DCE and APTW images could be used to detect IDH-1 mutation and Ki-67 expression in glioma patients before surgery. The prediction performance of the radiomics model based on the combination sequence was better than that of the single sequence model.

MRI and active surveillance: thoughts from across the pond.

In the United States (US), urological guidelines recommend active surveillance (AS) for patients with low-risk prostate cancer (PCa) and endorse it as an option for those with favorable intermediate-risk PCa with a > 10-year life expectancy. Multiparametric magnetic resonance imaging (mpMRI) is being increasingly used in the screening, monitoring, and staging of PCa and involves the combination of T2-weighted, diffusion-weighted, and dynamic contrast-enhanced T1-weighted imaging. The American Urological Association (AUA) guidelines provide recommendations about the use of mpMRI in the confirmatory setting for AS patients but do not discuss the timing of follow-up mpMRI in AS. The National Comprehensive Cancer Network (NCCN) discourages using it more frequently than every 12 months. Finally, guidelines state that mpMRI can be used to augment risk stratification but should not replace periodic surveillance biopsy. In this review, we discuss the current literature regarding the use of mpMRI for patients with AS, with a particular focus on the approach in the US. Although AS shows a benefit to the addition of mpMRI to diagnostic, confirmatory, and follow-up biopsy, there is no strong evidence to suggest that mpMRI can safely replace biopsy for most patients and thus it must be incorporated into a multimodal approach. CLINICAL RELEVANCE STATEMENT: According to the US guidelines, regular follow-ups are important for men with prostate cancer on active surveillance, and prostate MRI is a valuable tool that should be utilized, in combination with PSA kinetics and biopsies, for monitoring prostate cancer. KEY POINTS: According to the US guidelines, the addition of MRI improves the detection of clinically significant prostate cancer. Timing interval imaging of patients on active surveillance remains unclear and has not been specifically addressed. MRI should trigger further work-ups, but not replace periodic follow-up biopsies, in men on active surveillance.

MRI radiomics and biological correlations for predicting axillary lymph node burden in early-stage breast cancer

Background and aimsPreoperative prediction of axillary lymph node (ALN) burden in patients with early-stage breast cancer is pivotal for individualised treatment. This study aimed to develop a MRI radiomics model for evaluating the ALN burden in early-stage breast cancer and to provide biological interpretability to predictions by integrating radiogenomic data.MethodsThis study retrospectively analyzed 1211 patients with early-stage breast cancer from four centers, supplemented by data from The Cancer Imaging Archive (TCIA) and Duke University (DUKE). MRI radiomic features were extracted from dynamic contrast-enhanced MRI images and an ALN burden-related radscore was constructed by the backpropagation neural network algorithm. Clinical and combined models were developed, integrating ALN-related clinical variables and radscore. The Kaplan–Meier curve and log-rank test were used to assess the prognostic differences between the predicted high- and low-ALN burden groups in both Center I and DUKE cohorts. Gene set enrichment and immune infiltration analyses based on transcriptomic TCIA and TCIA Breast Cancer dataset were used to investigate the biological significance of the ALN-related radscore.ResultsThe MRI radiomics model demonstrated an area under the curve of 0.781–0.809 in three validation cohorts. The predicted high-risk population demonstrated a poorer prognosis (log-rank P < .05 in both cohorts). Radiogenomic analysis revealed migration pathway upregulation and cell differentiation pathway downregulation in the high radscore groups. Immune infiltration analysis confirmed the ability of radiological features to reflect the heterogeneity of the tumor microenvironment.ConclusionsThe MRI radiomics model effectively predicted the ALN burden and prognosis of early-stage breast cancer. Moreover, radiogenomic analysis revealed key cellular and immune patterns associated with the radscore.

Assessment of the O-RADS scoring system for the differentiation of different types of ovarian neoplasms: A modified approach with non-DCE-MRI

PurposeThe O-RADS MRI score stratifies adnexal mass risk with characteristics of T1-weighted, T2-weighed and dynamic contrast-enhanced (DCE) images. We explored a modified approach to evaluate the value of incorporation DWI/ADC with non-DCE-MRI in ORADS scoring system, and to assess the diagnostic performance and interreader consistency in differentiating ovarian neoplasm with different types. MethodsThis retrospective study included 218 women who underwent pelvic MRI with 221 ovarian tumors between January 2017 and December 2021. Two radiologists independently assessed each lesion using the original and modified O-RADS approach (incorporating DWI/ADC with non-DCE). Cohen's weighted-kappa and ROC analyses were employed to assess interreader consistency and diagnostic efficiency across all lesions and three ovarian neoplasms categories. ResultsThe area under the ROC curve (AUC) of the original protocol was 0.945 for all lesions and 0.947, 0.992, and 0.758 for the epithelial cell, germ cell and sex cord-stromal neoplasms. The modified approach achieved AUCs of 0.959 for all lesions and 0.962, 0.997, and 0.837 for the three categories. The interreader agreement was ‘excellent’ for all lesions and ‘good’ for the subgroups with the original protocol, improving to ‘excellent’ for all categories with the modified approach. ConclusionA modified O-RADS incorporating DWI/ADC with non-DCE MRI yields high diagnostic performance in differentiation of different types of ovarian neoplasms. It further improves consistency in subgroup interpretation. The modified approach can serve as an effective diagnostic tool without DCE, further promoting its adoption in primary hospitals.

Limited Utility of Dynamic Contrast Enhancement Imaging Sequences Within the PI-RADS v2.1 Classification Scheme: A Retrospective Cross-Sectional Study of MRI Reports.

Background/Objective: We sought to characterize the proportion of peripheral zone lesions "upgraded" within the PI-RADS v2.1 protocol using DCE imaging sequences in a large patient population undergoing multiparametric prostate MRI. Methods: A retrospective review of radiologist reports for 2742 prostate MRI exams at 2 large Alberta teaching hospitals between January 2017 and January 2022 was conducted. Prostate specific antigen (PSA), prostate volume, sequence specific and overall PI-RADS scores, and lesion positivity for DCE were collected if present in the accompanying radiology report. Further, pathology reports of biopsies of the upgraded lesions within upgraded patients were reviewed to see if upgraded lesions were deemed clinically significant by gleason score/grade group. Results: The median age was 63 years, with a median PSA and PSA density of 7.5 ng/mL and 0.13 ng/mL2 respectively. A total of 1809 lesions were reported, with 69.4% of all lesions being DCE positive. Of the lesions within the peripheral zone, 548 were overall PI-RADS 4. A total of 87/2742 (3.2%) of patients were upgraded to a PI-RADS 4 by DCE imaging. Within these patients, 65 had pathology reports available, of which 18 had a clinically significant lesion at the upgrade site. Conclusion: Contrast enhancement is only beneficial for a very small portion of patients undergoing prostate MRI. Given the invasive nature of contrast enhanced studies, potential contrast induced side effects, added imaging time, and the cost of contrast agent, routine use of contrast for prostate MRI is questioned. Further studies are necessary to determine if it should be part of routine prostate MRI imaging protocols.

Diffusion- and Perfusion-Weighted Imaging to Detect Neurological Deficits in Acute Focal Cerebral Ischemia in Rabbits.

To investigate the relationship of diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) parameters with dysfunction in acute focal cerebral ischemia (ACI) rabbits. The model of ACI in the middle cerebral artery was made using 30 adult male New Zealand rabbits. The dysfunction severities of the ACI rabbits were assessed using Purdy's score. A paired-sample rank sum test was adopted to compare the abnormal signal zone (ASZ) volumes from T2 weighted imaging (T2WI), dynamic susceptibility contrast-enhanced (DSC) imaging, and DWI with a relative cerebral blood flow (rCBF) map; correlations were analyzed between the volume of each ASZ and Purdy's score by Spearman's rank correlation coefficient. The degree of necrotic and apoptotic cells was evaluated in the ASZ from DWI and DSC PWI-DWI mismatch (PDM) zone. Correlations were analyzed between the index of cellular damage and Purdy's score, the volume of ASZs by Spearman's rank correlation coefficient. The ASZ volumes from DSC-PWI and the rCBF maps were larger than those from DWI (p < 0.001 and p < 0.001, respectively); those from the rCBF map (Z = 0.959, p < 0.001) and DSC-PWI (Z = 0.970, p < 0.001) were positively correlated with DWI; a positive correlation was found between Purdy's score and the ASZ volumes from DSC-PWI (Z = 0.889, p < 0.001), DWI (Z = 0.921, p < 0.001), and rCBF (Z = 0.891, p < 0.001). A significant difference was observed between the ASZ from DWI and the PDM zone in terms of the degree of necrotic (p < 0.001) and apoptotic cells (p < 0.001). The degree of cellular damage in the ASZ of DWI and PDM zone had no relationship with Purdy's score and the volumes of ASZs. The ASZ volumes from DSC-PWI, rCBF, and particularly DWI reflected the level of dysfunction in rabbits with ACI.

3D MR fingerprinting for dynamic contrast-enhanced imaging of whole mouse brain.

Quantitative MRI enables direct quantification of contrast agent concentrations in contrast-enhanced scans. However, the lengthy scan times required by conventional methods are inadequate for tracking contrast agent transport dynamically in mouse brain. We developed a 3D MR fingerprinting (MRF) method for simultaneous T1 and T2 mapping across the whole mouse brain with 4.3-min temporal resolution. We designed a 3D MRF sequence with variable acquisition segment lengths and magnetization preparations on a 9.4T preclinical MRI scanner. Model-based reconstruction approaches were employed to improve the accuracy and speed of MRF acquisition. The method's accuracy for T1 and T2 measurements was validated in vitro, while its repeatability of T1 and T2 measurements was evaluated in vivo (n = 3). The utility of the 3D MRF sequence for dynamic tracking of intracisternally infused gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in the whole mouse brain was demonstrated (n = 5). Phantom studies confirmed accurate T1 and T2 measurements by 3D MRF with an undersampling factor of up to 48. Dynamic contrast-enhancedMRF scans achieved a spatial resolution of 192 × 192 × 500 μm3 and a temporal resolution of 4.3 min, allowing for the analysis and comparison of dynamic changes in concentration and transport kinetics of intracisternally infused Gd-DTPA across brain regions. The sequence also enabled highly repeatable, high-resolution T1 and T2 mapping of the whole mouse brain (192 × 192 × 250 μm3) in 30 min. We present the first dynamic and multi-parametric approach for quantitatively tracking contrast agent transport in the mouse brain using 3D MRF.

Prospective close monitoring of the effect of vascular-targeted photodynamic therapy and high intensity focused ultrasound of localized prostate cancer by multiparametric magnetic resonance imaging.

The aim of this study is to describe the anatomical and functional changes observed in multiparametric magnetic resonance imaging (mpMRI) during follow-up after focal therapy (FT) for localized prostate cancer (PCa). In this prospective study, we analyzed pre- and postoperatively acquired mpMRI of 10 patients after FT (7days; 3, 6, 9, 12months). 7/10 (70%) patients underwent vascular-targeted photodynamic therapy (VTP). 3/10 (30%) patients underwent high-intensity focused ultrasound (HIFU). MpMR image analysis was performed using a semi-automatic software for segmentation of the prostate gland (PG) and tumor zones. Signal intensities (SI) of T2-weighted (T2w), T1-weighted (T1w),diffusion-weighted (DWI) and dynamic contrast-enhanced (DCE) images as well as volumes of the prostate gland (PGV) and tumor volumes (TV) were evaluated at each time point. The results showed a significant increase of PGV 7days after FT (p = 0.042) and a significant reduction of PGV between 7days and 6, 9 and 12months after FT (p < 0.001). The TV increased significantly 7days after FT (p < 0.001) and decreased significantly between 7days and 12months after FT (p < 0.001). There was a significant increase in SI of the ADC in the ablation zone after 6, 9 and 12months after FT (p < 0.001). 1/9 patients (11%) had recurrent tumor on rebiopsy characterized as a a small focal lesion on mpMRI with strong diffusion restriction (low SI on ADC map and high SI on b-value DWI). MpMRI is able to represent morphologic changes of the ablated zone after FT and might be helpful to detect recurrent tumor.

Can dynamic contrast-enhanced MR imaging based on radiomics improve the diagnostic efficiency of clinically significant prostate cancer?

Aims/Background Prostate cancer stands out as one of the most prevalent malignant tumours among males. The non-invasive identification of clinically significant prostate cancer via magnetic resonance imaging plays a critical role in circumventing unnecessary biopsies and determining suitable treatment strategies for patients. Our study aimed to evaluate the potential improvement in predictive accuracy for clinically significant prostate cancer by incorporating perfusion data obtained from dynamic contrast-enhanced magnetic resonance imaging acquisition protocols into multiparametric magnetic resonance imaging parameters. Methods Radiomics extracted from perfusion parameters (Ktrans, Kep, Ve) of dynamic contrast-enhanced magnetic resonance imaging were analysed in patients suspected of prostate cancer who underwent 3T multiparametric magnetic resonance imaging between January 2017 and June 2023 in this retrospective study. The pathological findings obtained from biopsy or therapy were categorised into groups based on the Gleason sum score as either clinically significant prostate cancer (Gleason sum score > 7) or non-clinically significant prostate cancer (Gleason sum score ≤ 6). Diagnostic models were constructed using logistic regression analysis, incorporating prostate imaging reporting and data system V2.1 scores and clinical data, with or without radiomics extracted from dynamic contrast-enhanced. The area under curve (AUC) values were compared using the DeLong test. Results Overall, 214 men (clinically significant prostate cancer [n=78] and non-clinically significant prostate cancer [n=136]) were included. The clinical-prostate imaging reporting and data system model demonstrated an AUC of 0.89 (95% confidence interval: 0.84-0.95) in the training cohort and 0.91 (95% confidence interval: 0.84-0.98) in the test cohort. For the clinical-prostate imaging reporting and data system-radscore model, the AUC values were 0.97 (95% confidence interval: 0.95-0.99) for Ktrans, 0.98 (95% confidence interval: 0.96-1.00) for Ve, and 0.96 (95% confidence interval: 0.93-0.98) for Kep in the training cohort, and 0.97 (95% confidence interval: 0.94-1.00) for Ktrans, 0.95 (95% confidence interval: 0.91-1.00) for Ve, and 0.97 (95% confidence interval: 0.94-1.00) for Kep in the test cohort. Radiomics based on perfusion parameters exhibited good diagnostic performance in predicting clinically significant prostate cancer. The clinical-prostate imaging reporting and data system-radscore model demonstrated superior diagnostic capability compared to perfusion-based radiomics or clinical-prostate imaging reporting and data system models alone. Conclusion The application of radiomics, which involves extracting perfusion parameters from dynamic contrast-enhanced imaging, has the potential to enhance diagnostic accuracy for clinically significant prostate cancer.

Image quality comparison of 1.5T and 3T prostate MRIs of the same post-hip arthroplasty patients: multi-rater assessments including PI-QUAL version 2.

To compare the image quality of 1.5T and 3T prostate MRIs of the same post-hip arthroplasty patients, with a specific focus on the degree of susceptibility artifacts. This single-center retrospective study included post-hip arthroplasty patients who underwent 1.5T prostate MRIs between 2021 and 2023, as well as comparative 3T prostate MRIs. Three blinded abdominal radiologists retrospectively reviewed their diffusion-weighted imaging (DWI, 50s/mm2), T2-weighted imaging (T2WI), and dynamic contrast-enhanced imaging (DCE) to evaluate the image quality. The degree of susceptibility artifacts was categorized using a three-point scale, with 3 indicating the least artifact and 1 indicating the most. Image quality was also evaluated using Prostate Imaging Quality (PI-QUAL) version 2. The median of the three raters' scores was compared between 1.5T and 3T prostate MRIs using the Wilcoxon signed-rank test. The inter-rater agreement was evaluated using the multi-rater generalized kappa. Twenty pairs of 1.5T and 3T prostate MRI examinations from 20 unique patients were included. The DWI susceptibility artifact score at 1.5T was significantly higher than at 3T (mean score ± standard deviation, 2.80 ± 0.41 vs. 2.35 ± 0.93, p = 0.014). In contrast, no significant differences were observed in the susceptibility artifact scores in T2WI and DCE, or in the PI-QUAL score. The inter-reader agreement in the susceptibility artifact score was moderate (multi-rater generalized kappa: 0.60) in DWI, perfect in T2WI (not applicable), andsubstantial (0.65) in DCE. The inter-reader agreement wasfair (0.27) in the PI-QUAL score. Using 1.5T scanners may be preferable to reduce susceptibility artifacts from hip prostheses in DWI.

MRI versus Dual-Energy CT in Local-Regional Staging of Gastric Cancer.

Background Preoperative local-regional tumor staging of gastric cancer (GC) is critical for appropriate treatment planning. The comparative accuracy of multiparametric MRI (mpMRI) versus dual-energy CT (DECT) for staging of GC is not known. Purpose To compare the diagnostic accuracy of personalized mpMRI with that of DECT for local-regional T and N staging in patients with GC receiving curative surgical intervention. Materials and Methods Patients with GC who underwent gastric mpMRI and DECT before gastrectomy with lymphadenectomy were eligible for this single-center prospective noninferiority study between November 2021 and September 2022. mpMRI comprised T2-weighted imaging, multiorientational zoomed diffusion-weighted imaging, and extradimensional volumetric interpolated breath-hold examination dynamic contrast-enhanced imaging. Dual-phase DECT images were reconstructed at 40 keV and standard 120 kVp-like images. Using gastrectomy specimens as the reference standard, the diagnostic accuracy of mpMRI and DECT for T and N staging was compared by six radiologists in a pairwise blinded manner. Interreader agreement was assessed using the weighted κ and Kendall W statistics. The McNemar test was used for head-to-head accuracy comparisons between DECT and mpMRI. Results This study included 202 participants (mean age, 62 years ± 11 [SD]; 145 male). The interreader agreement of the six readers for T and N staging of GC was excellent for both mpMRI (κ = 0.89 and 0.85, respectively) and DECT (κ = 0.86 and 0.84, respectively). Regardless of reader experience, higher accuracy was achieved with mpMRI than with DECT for both T (61%-77% vs 50%-64%; all P < .05) and N (54%-68% vs 51%-58%; P = .497-.005) staging, specifically T1 (83% vs 65%) and T4a (78% vs 68%) tumors and N1 (41% vs 24%) and N3 (64% vs 45%) nodules (all P < .05). Conclusion Personalized mpMRI was superior in T staging and noninferior or superior in N staging compared with DECT for patients with GC. Clinical trial registration no. NCT05508126 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Méndez and Martín-Garre in this issue.

Pictorial review of the diagnosis of muscle-invasive bladder cancer using vesical imaging-reporting and data system (VI-RADS).

The Vesical Imaging-Reporting and Data System (VI-RADS) is a standard magnetic resonance imaging (MRI) and diagnostic method for muscle-invasive bladder cancer that was published in 2018. Several studies have demonstrated that VI-RADS has high diagnostic power and reproducibility. However, reading VI-RADS requires a certain amount of expertise, and radiologists need to be aware of the various pitfalls. MRI of the bladder includes T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCEI). T2WI is excellent for understanding anatomy. DWI and DCEI show high contrast between the tumor and normal anatomical structures and are suitable for staging local tumors. Bladder tumors are classified into five categories according to their size and morphology and their positional relationship to the bladder wall based on the VI-RADS diagnostic criteria. If the T2WI, DWI, and DCEI categories are the same, the category is the VI-RADS category. If the categories do not match, the DWI category is the VI-RADS category. If image quality of DWI is not evaluable, the DCEI category is the final category. In many cases, DWI is dominant, but this does not mean that T2WI and DCEI can be omitted from the reading of the bladder. In this educational review, typical and atypical teaching cases are demonstrated, and how to resolve misdiagnosis and the limitations of VI-RADS are discussed. The most important aspect of VI-RADS reading is to practice multiparametric reading with a solid understanding of the characteristics and role of each sequence and an awareness of the various pitfalls.

PI-RADS 2.1: A Practical Overview

AbstractThe Prostate Imaging Reporting and Data System (PI-RADS) is an essential tool for standardizing the interpretation of multiparametric magnetic resonance imaging (mp-MRI) of the prostate for detecting prostate cancer. This article provides a comprehensive overview of the latest version, PI-RADS 2.1, with clear pictures to guide radiologists in its practical application for improved diagnostic accuracy. The article explores the key modifications, emphasizing the changes in scoring criteria and their impact on clinical decision-making. It discusses the importance of mp-MRI sequences, such as T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging, and clarifies their significance in the PI-RADS 2.1 framework. The article highlights practical insights to help radiologists integrate this updated system into their day-to-day practice, promoting consistency and reliability in reporting.

Detail-preserving image warping by enforcing smooth image sampling

Multi-phase dynamic contrast-enhanced magnetic resonance imaging image registration makes a substantial contribution to medical image analysis. However, existing methods (e.g., VoxelMorph, CycleMorph) often encounter the problem of image information misalignment in deformable registration tasks, posing challenges to the practical application. To address this issue, we propose a novel smooth image sampling method to align full organic information to realize detail-preserving image warping. In this paper, we clarify that the phenomenon about image information mismatch is attributed to imbalanced sampling. Then, a sampling frequency map constructed by sampling frequency estimators is utilized to instruct smooth sampling by reducing the spatial gradient and discrepancy between all-ones matrix and sampling frequency map. In addition, our estimator determines the sampling frequency of a grid voxel in the moving image by aggregating the sum of interpolation weights from warped non-grid sampling points in its vicinity and vectorially constructs sampling frequency map through projection and scatteration. We evaluate the effectiveness of our approach through experiments on two in-house datasets. The results showcase that our method preserves nearly complete details with ideal registration accuracy compared with several state-of-the-art registration methods. Additionally, our method exhibits a statistically significant difference in the regularity of the registration field compared to other methods, at a significance level of p < 0.05. Our code will be released at https://github.com/QingRui-Sha/SFM.

Deep Learning-Based Approach for Identifying and Measuring Focal Liver Lesions on Contrast-Enhanced MRI.

The number of focal liver lesions (FLLs) detected by imaging has increased worldwide, highlighting the need to develop a robust, objective system for automatically detecting FLLs. To assess the performance of the deep learning-based artificial intelligence (AI) software in identifying and measuring lesions on contrast-enhanced magnetic resonance imaging (MRI) images in patients with FLLs. Retrospective. 395 patients with 1149 FLLs. The 1.5 T and 3 T scanners, including T1-, T2-, diffusion-weighted imaging, in/out-phase imaging, and dynamic contrast-enhanced imaging. The diagnostic performance of AI, radiologist, and their combination was compared. Using 20 mm as the cut-off value, the lesions were divided into two groups, and then divided into four subgroups: <10, 10-20, 20-40, and ≥40 mm, to evaluate the sensitivity of radiologists and AI in the detection of lesions of different sizes. We compared the pathologic sizes of 122 surgically resected lesions with measurements obtained using AI and those made by radiologists. McNemar test, Bland-Altman analyses, Friedman test, Pearson's chi-squared test, Fisher's exact test, Dice coefficient, and intraclass correlation coefficients. A P-value <0.05 was considered statistically significant. The average Dice coefficient of AI in segmentation of liver lesions was 0.62. The combination of AI and radiologist outperformed the radiologist alone, with a significantly higher detection rate (0.894 vs. 0.825) and sensitivity (0.883 vs. 0.806). The AI showed significantly sensitivity than radiologists in detecting all lesions <20 mm (0.848 vs. 0.788). Both AI and radiologists achieved excellent detection performance for lesions ≥20 mm (0.867 vs. 0.881, P = 0.671). A remarkable agreement existed in the average tumor sizes among the three measurements (P = 0.174). AI software based on deep learning exhibited practical value in automatically identifying and measuring liver lesions. Stage 2.

Evaluation of treatment response by multiparametric MR imaging in locally advanced rectal tumors following neoadjuvant chemotherapy.

To investigate the effectiveness of multiparametric MRI examination in determining tumor response after neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal tumors. 46 patients with locally advanced rectal adenocarcinoma were included and were divided into two groups as complete responders and nonresponders based on Mandard score. On MRI, relative T2w signal intensity and ADC values obtained before and after treatment and tumour volumes in dynamic contrast enhanced images (DCI) were used to determine complete response to treatment. There were no significant differences between mean ADC values obtained by single slice ADC and three circular ROI methods. There were significant differences between two groups in terms of Post-CRT ADC value, ΔADC and %ΔADC obtained by whole tumour volume ADC method (p < 0.05). There were significant differences between Pre-CRT and Post-CRT volume values. ΔV DCI and %ΔV DCI, ΔV ADC and T2w volume values were significantly lower in complete responders (p < 0.05). In multivariate analysis, sensitivity and specificity were calculated as 88.9% and 91.9% (AUC = 0.943) when Post-CRT mean ADC value and Post-CRT DCI volume values were used together, and sensitivity and specificity were calculated as 88.9% and 94.6% (AUC = 0.949) when ΔADC and Post-CRT DCI volume values were used together. Whole tumour volume mean ADC value is the most useful method to determine treatment response. Post-CRT DCI volume measurement stands out as the most useful method in assessing complete response alone. The highest diagnostic values are achieved when the post-CRT DCI volume is combined with the ADC change value of the whole tumor volume.